Nimotuzumab with chemoradiation confers a survival advantage in treatment-naïve head and neck tumors over expressing EGFR.

摘要: Head and neck cancer associated with the chewing of betel preparations, including tobacco, is common to South East Asia. We report a Phase IIB study in which ninety-two treatment naive patients advanced squamous cell carcinoma received standard therapy or without an anti-Epidermal Growth Factor Receptor (EGFR) monoclonal antibody (Nimotuzumab). In pretreatment samples, tissue expression ErbB family proteins downstream molecules, their association clinical response survival. Marker tumor adjacent sections was evaluated by immunohistochemistry. The benefit Nimotuzumab (200 mg/dose, once week for six weeks) combination radiotherapy chemoradiation assessed respect EGFR intensity. Two antibodies, recognized independent epitopes, were used assess levels detection using mR3, similar specificity Nimotuzumab, correlated significantly ErbB3 (p<0.05), PCNA pMAPK (p<0.001). Although showed significant relationship patient survival treated (p=0.02), did not (p=0.07). Interestingly, overexpression (as defined mR3) directly overall this group (p=0.01). This data supports model basal activation signal transduction pathway these oropharyngeal tumors. Detection immunohistochemistry could define subset Neck who may from receiving targeted therapies chemoradiation.